Acne can return after isotretinoin. A few superficial spots, recurring deep nodules and marks left by the original acne represent different situations, so they should not all lead to the same response. A repeat course is one possible option for selected patients, not the automatic answer to the first new lesion.
The dermatologist needs to assess what has returned, how soon it appeared and how the original course went. That review can identify a maintenance treatment or a reason to reconsider the diagnosis before another systemic prescription.
What counts as relapse?
In ordinary conversation, relapse may mean any new spot. Research often uses a narrower definition, such as restarting a systemic acne medicine. Those definitions produce different percentages and explain why two studies can appear to disagree without measuring the same event.
A flat red or brown mark is not an active lesion, and a scar does not establish that acne has restarted. Examine the new pattern rather than judge only whether your skin looks perfectly uniform.
If you notice a few lesions, document their frequency and type. Increasing tenderness, deep inflammation or new scarring deserves earlier review than an occasional small spot that resolves.
What the 2025 cohort study found
A study of 19,907 patients found that 22.5% later received systemic acne treatment consistent with the study's relapse definition, while 8.2% underwent another isotretinoin course. The investigators used insurance claims and included patients who completed an initial course lasting at least four months. 1
Those numbers do not predict a universal chance of relapse. Claims data record care and prescriptions rather than a detailed examination of every lesion. The study also cannot account completely for differences in acne severity, treatment decisions or patients who managed mild recurrence without another systemic prescription.
The findings support the idea that recurrence and repeat isotretinoin treatment are different outcomes. Many patients who need further acne treatment do not need another course of the same medicine.
Why acne may return
Acne can remain biologically active after a successful course. Hormonal patterns, the original disease and the amount of exposure achieved can influence later control. A course interrupted by adverse effects or access problems also differs from one completed as planned.
The cohort study found associations between greater cumulative exposure and lower relapse or repeat-course rates. It did not establish that pursuing a higher daily dose at any cost produces the best result for every patient. Daily tolerability and the full course still matter. 1
New medicines, testosterone or anabolic steroid use, irritating products and a different skin condition can also affect the later pattern. Mention changes since the first course instead of assuming the original prescription alone explains every new lesion.
The first assessment after treatment
Skin may continue improving after the final capsule. The cited US labels advise waiting at least two months before considering another course. That interval gives the clinician a better view of the final response rather than treating residual early activity as an immediate failure. 3, 4
Bring the formulation, approximate dose history, dates and reason for stopping. Include how long you remained clear and whether recurrent lesions resemble the original acne. Photos from before, during and after treatment can show a pattern that a single examination misses.
The clinician should also review any adverse effects that persisted. A second course needs another safety decision, not simply a copy of the earlier prescription.
Maintenance treatment
Some patients benefit from a topical treatment after isotretinoin, while others need no regular prescription once the skin settles. NICE recommends considering maintenance for people with a history of frequent relapse and describes options based on adapalene with benzoyl peroxide or an appropriate alternative when that combination does not suit the patient. 2
Timing matters. Skin that remains dry and sensitive may not tolerate immediate daily use of a topical retinoid. The prescriber can plan when to begin, how to introduce it and what to do if irritation develops.
Do not restart every product used before the course. A maintenance routine should have a clear purpose and be simple enough to continue, with a review if new acne still develops.
Choosing treatment for recurrent lesions
The severity of recurrence guides the next step. Mild disease may respond to a topical regimen. More substantial inflammatory acne may need another prescription approach, while severe nodular recurrence can lead to a discussion of another isotretinoin course. 2, 5
| Current pattern | A possible discussion | What should not happen automatically |
|---|---|---|
| Occasional superficial spots | Skin care review or a topical plan | Restarting leftover isotretinoin |
| Repeated inflammatory acne | A reassessment and an evidence-based combination regimen | Indefinite antibiotic treatment without review |
| Deep painful nodules or new scars | Earlier specialist assessment | Waiting through months of scarring to prove recurrence |
| Persistent marks without new lesions | Assessment of pigmentation or scars | Treating every visible mark as active acne |
The clinician may also consider hormonal treatment for an appropriate patient. A different mechanism can suit a later acne pattern even when isotretinoin helped the original disease.
A second course needs fresh preparation
A previous course does not remove pregnancy risk or guarantee the same tolerability. The prescriber must review current health, medicines, laboratory results and applicable prevention requirements again. Plans about pregnancy, breastfeeding or other treatment may have changed.
Old capsules do not replace that process. Their strength or formulation may not match a new plan, and a previous authorization does not create indefinite access to treatment.
Ask what the second course aims to change and how the prescriber will judge its endpoint. The discussion should cover the earlier response and adverse effects rather than promise that repeating the same treatment will guarantee permanent clearance.
Did I cause the relapse by using the wrong cleanser?
Not necessarily. Acne can recur despite reasonable skin care. A product may irritate or aggravate skin, but recurrence does not establish a personal mistake. Assess the disease pattern before blaming a single routine choice.
Does a small breakout mean the first course was wasted?
No. A course can provide prolonged improvement without eliminating every future lesion. The relevant question is how much active disease has returned and which treatment fits it now.
Should I increase a maintenance cream when acne returns?
Follow the prescribed schedule and arrange review if it does not control the new pattern. More frequent application can add irritation without addressing the reason the acne has changed.
Sources
- Lai J, et al. Acne relapse and isotretinoin retrial in patients with acne. JAMA Dermatology, 2025. View source
- NICE. Acne vulgaris: management, NG198. Recommendations, updated 2026. View source
- DailyMed. Isotretinoin capsules prescribing information, revised August 2026. View source
- FDA. Absorica and Absorica LD prescribing information, revised June 2026. View source
- American Academy of Dermatology. Updated guidelines for acne management, 2024. View source